Company profile: T3 Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of innovative bacterial cancer therapies using engineered live bacteria to deliver immune-modulating proteins directly to cancer cells and the tumor micro-environment. Offers a proprietary bacterial cancer therapy platform and develops T3P-Y058-739, a lead candidate delivering proteins into solid tumors to induce a specific immune response.
Products and services
- Bacterial Cancer Therapy Platform: A proprietary platform utilizing live bacteria engineered to deliver immune-modulating proteins directly to cancer cells and the tumor micro-environment, supporting precise immune modulation at the tumor site
- Highly Innovative Cancer Treatments: The company architects targeted medicines to improve the lives of cancer patients by developing highly specific and efficient treatments that address gaps left by classical therapies
- T3P-Y058-739: An engineered-bacteria-based lead therapeutic candidate that delivers proteins into solid tumors to induce a specific immune response against cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to T3 Pharmaceuticals
Intact Medical
HQ: United States
Website
- Description: Provider of minimally invasive systems for volumetric excision of tissue for diagnostic and therapeutic applications in select cancer markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Intact Medical company profile →
Vaxess
HQ: United States
Website
- Description: Provider of needle-free vaccine and therapeutic delivery solutions, offering the MIMIX applicator with patch for skin-based administration and silk fibroin biomaterials that create stable, biocompatible delivery systems, with a focus on improving access to vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxess company profile →
PharmaMar
HQ: Spain
Website
- Description: Provider of oncology medicines inspired by the sea, discovering antitumor molecules from marine organisms through integrated research and development. Delivers innovative products to equip healthcare professionals with new tools to treat cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PharmaMar company profile →
PanTher Therapeutics
HQ: United States
Website
- Description: Provider of localized cancer therapies leveraging the Sagittari platform to optimize drug dose and duration for high-dose, tumor-targeted treatment with minimal systemic exposure. Offers PTM-101, a clinical-stage candidate delivering high concentrations of paclitaxel to pancreatic tumors via minimally invasive laparoscopy, and exploratory programs for pancreatic, colon, and lung cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PanTher Therapeutics company profile →
Immunitas Therapeutics
HQ: United States
Website
- Description: Provider of single-cell genomics and machine learning-based drug discovery to modulate oncology targets; antibody discovery and engineering; biomarker development; and IMT-009, an immuno-oncology a-CD161 mAb in clinical evaluation for solid tumors and hematological malignancies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunitas Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for T3 Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to T3 Pharmaceuticals
2.2 - Growth funds investing in similar companies to T3 Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for T3 Pharmaceuticals
4.2 - Public trading comparable groups for T3 Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →